AbbVie , a research-based global biopharmaceutical company, announced it will present data about the company’s portfolio of investigational oncology medicines during the American Society of Clinical Oncology (ASCO) Annual Meeting, June 1-5, in Chicago. More than 30 abstracts have been accepted, featuring data in hematologic malignancies and several solid tumor types, including brain cancer and lung cancer.
Researchers will present data across multiple hematologic malignancies evaluating venetoclax, a first-in-class BCL-2 inhibitor developed by AbbVie and Genentech, and ibrutinib, an inhibitor of Bruton’s tyrosine kinase (BTK).
Additionally, updated data will be featured from AbbVie’s late-stage investigational products including depatuxizumab mafodotin (depatux-m; previously known as ABT-414), an antibody-drug conjugate (ADC), in amplified-epidermal growth factor receptor (EGFR) recurrent glioblastoma (rGBM); rovalpituzumab tesirine (Rova-T), an investigational ADC targeting delta-like protein 3 (DLL3)-expressing tumors, in small cell lung cancer (SCLC); veliparib, an investigational oral poly (adenosine diphosphate [ADP]–ribose) polymerase (PARP) inhibitor, across multiple solid tumors; elotuzumab, an immunostimulatory antibody that specifically targets signaling lymphocyte activation molecule family member 7 (SLAMF7), a cell-surface glycoprotein; as well as other early-stage investigational compounds, including ABBV-075 (Mivebresib), ABT-165 and PF-06647020 (PF-7020).
In oncology discovery and early development, AbbVie utilizes key therapeutic pathways and methods to identify appropriate options to treat people living with cancer. Abstracts at ASCO 2018 will also show progress in AbbVie’s discovery and early development efforts.
“AbbVie’s data at ASCO 2018 reinforces the potential of our robust oncology portfolio, focused on helping patients impacted by several different cancers where few durable treatment options exist,” said Neil Gallagher, M.D., vice president and head of global oncology development, AbbVie. “We concentrate our efforts on delivering meaningful medicines for patients, and are committed to advancing science aimed at the most difficult-to-treat cancers.”
To learn more about our work in oncology, visit http://abbvieoncology.com.
About AbbVie in Oncology
At AbbVie, we strive to discover and develop medicines that deliver transformational improvements in cancer treatment by uniquely combining our deep knowledge in core areas of biology with cutting-edge technologies, and by working together with our partners – scientists, clinical experts, industry peers, advocates, and patients. We remain focused on delivering these transformative advances in treatment across some of the most debilitating and widespread cancers. We are also committed to exploring solutions to help patients obtain access to our cancer medicines. With the acquisitions of Pharmacyclics in 2015 and Stemcentrx in 2016, our research and development efforts, and through collaborations, AbbVie’s oncology portfolio now consists of marketed medicines and a pipeline containing multiple new molecules being evaluated worldwide in more than 200 clinical trials and more than 20 different tumor types. For more information, please visit http://abbvieoncology.com.
AbbVie is a global, research and development-based biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.com